A. The Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA), permits veterinarians to prescribe extralabel uses of approved human and animal drugs for animals under certain conditions. Extralabel use must comply with all the provisions of AMDUCA and its implementing regulation at 21 CFR § 530. Among other limitations, these provisions allow extralabel use of a drug only on the lawful order of a licensed veterinarian in the context of a valid veterinarian-client-patient relationship and only in circumstances when the health of an animal is threatened or suffering, or death may result from failure to treat.
A. No. Based on available evidence, FDA has concluded that THC and CBD products are excluded from the dietary supplement definition under section 201(ff)(3)(B) of the FD&C Act [21 U.S.C. § 321(ff)(3)(B)]. Under that provision, if a substance (such as THC or CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act [21 U.S.C. § 355], or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are excluded from the definition of a dietary supplement. FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under FDA’s regulations (21 CFR 312.2), unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.
A. To date, the agency has not approved a marketing application for cannabis for the treatment of any disease or condition. FDA has, however, approved one cannabis-derived and three cannabis-related drug products. These approved products are only available with a prescription from a licensed healthcare provider.
Children and Pregnant/Lactating Women
26. Can approved human drugs containing CBD or synthetic THC be used extralabel in animals?
Conducting clinical research using cannabis-related substances that are scheduled by the DEA often involves interactions with several federal agencies. This includes: a registration administered by the DEA; obtaining the cannabis for research from NIDA, within the National Institutes of Health, or another DEA-registered source; and review by the FDA of the IND or INAD application and research protocol. Additionally:
A. FDA is aware that unapproved cannabis or cannabis-derived products are being used for the treatment of a number of medical conditions including, for example, AIDS wasting, epilepsy, neuropathic pain, spasticity associated with multiple sclerosis, and cancer and chemotherapy-induced nausea.
In addition, under 21 CFR 530.20, extralabel use of an approved human drug in a food-producing animal is not permitted if an animal drug approved for use in food-producing animals can be used in an extralabel manner for the use. In addition, under 21 CFR 530.20(b)(2), if scientific information on the human food safety aspect of the use of the approved human drug in food-producing animals is not available, the veterinarian must take appropriate measures to ensure that the animal and its food products will not enter the human food supply.
For more information on extralabel use of FDA approved drugs in animals, see Extralabel Use of FDA Approved Drugs In Animals.
The myriad ways in which it works are not fully understood, but do not appear to center on the CB1 and CB2 receptors that THC acts on. Those receptors are part of the relatively newly-discovered endocannabinoid system, first described in 1992,  and increasingly found to be important to human health and well-being through maintaining homeostasis (balance) in various aspects of physiology.     CBD actually opposes the action of THC at the CB1 receptor (and certain other receptors as well), which can help counter THC’s (potential) worsening of cognition, memory, psychosis, and other effects.   Most notably, you won’t get “high” (at least in the conventional sense of the word) from CBD, due to its differential impact on CB1 compared to THC. 
Two reasons. First, isolated CBD won’t get you “high”, unlike THC (the other main cannabinoid in cannabis). Second, isolated CBD has shown a ton of promise in animal research for the treatment of (anxiety, pain, inflammation, cancer, etc). Unfortunately, as of as of 2019, there are relatively few human trials. And unregulated CBD often contains way lower or higher doses than the label states, sometimes even containing unlisted THC. Things are heating up though: in 2018, the FDA approved the first CBD pharmaceutical (Epidiolex ® ) for two rare types of epilepsy. Stay tuned to this page, as nearly 190 trials are underway!
This page is regularly updated, to include the most recently available clinical trial evidence.
Is CBD dangerous?
Despite this, CBD appears to be much safer than many other treatments aimed at chronic pain and anxiety, as well as drugs used for recreational use. In fact, the World Health Organization concluded in a review: “to date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD”. 
Before protesting, “Hey, why doesn’t your Scientific Research section cover XYZ mouse study showing CBD benefits?”, take note that mice are not human. In fact, the same exact dose of CBD in a mouse versus a human will be more bioavailable in the mouse, leading to larger effects.  That’s besides the bevy of other reasons that animal studies often don’t translate to humans, such as different metabolic pathways in animals, lab conditions differing from free-living human conditions, etc. 
This page features 120 references. All factual claims are followed by specifically-applicable references. Click here to see the full set of references for this page.
Anywho, back to CBD’s main effects. It appears to impact a variety of other receptors in the body, including an important receptor involved in pain and stress response, called TRPV1.    Other receptors that CBD impacts include GPR55, 5HTI-alpha, and adenosine A2A, which variously can help with inflammation, pain, anxiety, and even potentially cancer.    
The efficacy of CBD oil capsules and softgels vary from one product to the next, depending on the quality. Here are a few factors to keep in mind:
Cornbread Hemp’s CBD oil capsules are regularly tested to be 100% free of pesticides, heavy metals, mycotoxins, and microbials. These full spectrum extracts also are a true “whole plant” product, meaning they contain a full range of cannabinoids, including a legal amount of THC.
Joy Organics softgels with melatonin are designed to support healthy sleep cycles. Melatonin has been shown to promote relaxation and alongside CBD it may help you rest easier.
Best THC-Free: Medterra CBD Gel Capsules
Prima CBD pills are designed to help combat stress and target issues at their source. Prima holds itself to the highest social and environmental standards and is a certified B Corp. Each of these vegan softgels contain 25 milligrams of CBD, which makes them a subtle, daily dose of hemp extract.
It should also be said that a dropper of hemp oil has an earthy taste, which isn't to everyone's liking. A CBD tablet or softgel allows you to avoid this bitter flavor with one quick and easy swallow.
When evaluating each CBD capsule brand, we considered the following factors: the type of hemp extract, the extraction method, and hemp source. Each product has also been reviewed by a third-party laboratory for label accuracy and potential contaminants, including pesticides, heavy metals, and residual solvents. We also considered the amount of CBD in each capsule and the overall price to select the best available products.
More recently, easy-to-take products like CBD pills and capsules have been growing in popularity. These offer a simple way to supplement your wellness plan with CBD, especially if you don't enjoy the taste of CBD oil tinctures or want an on-the-go option.